Find A Clinical Trial

Disease Type: Multiple Hematologic

Trial ID ERAS-007-04
Sponsor ID HERKULES-4

A Phase 1b/2 Master Protocol of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Hematologic Malignancies (HERKULES-4).

Trial ID 21469
Sponsor ID LOTIS 9

A Phase 2 open-label study of loncastuximab tesirine in combination with rituximab (Lonca-R) in previously untreated unfit/frail patients with diffuse large B-cell lymphoma (DLBCL) (LOTIS-9/ ADCT-402-203)

Principal Investigator
Mitul Gandhi, MD
Trial ID 21356
Sponsor ID Genentech

AN OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Principal Investigator
Mitul Gandhi, MD
Trial ID 21171
Sponsor ID Novartis

A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (CABL001J12301)

Principal Investigator
Mitul Gandhi, MD
Trial ID SET-101
Sponsor ID Epizyme, Inc.

A Phase 1/1b, Open-Label Multi Center Two Part Study of SETD2 Inhibitor EZM414 in Subjects with Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Trial ID M20-178
Sponsor ID TRANSFORM-2

A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis

Principal Investigator
Mitul Gandhi, MD
Trial ID 20346
Sponsor ID XPORT-MF-035

A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor Versus Treatment of Physician’s Choice in Patients with Previously Treated Myelofibrosis

Principal Investigator
Mitul Gandhi, MD
Trial ID 20177
Sponsor ID TRANSFORM-1, M16-191

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib in Subjects with Myelofibrosis

Principal Investigator
Mitul Gandhi, MD